|333.48||-19.51||-5.53%||Vol 2.57M||1Y Perf 435.56%|
|Sep 24th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||290.88||Analyst Rating||Moderate Buy 2.14|
|Potential %||-12.77||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★★ 65.78|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★★ 74.27|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||67.59||Earnings Rating||—|
|Market Cap||80.87B||Earnings Date||9th Nov 2021|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||9th Nov 2021|
|Estimated EPS Next Report||10.68|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.42M|
|Avg. Monthly Volume||3.02M|
|Avg. Quarterly Volume||4.14M|
BioNTech SE (NASDAQ: BNTX) stock closed at 333.48 per share at the end of the most recent trading day (a -5.53% change compared to the prior day closing price) with a volume of 2.60M shares and market capitalization of 80.87B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1310 people. BioNTech SE CEO is Ugur Sahin.
The one-year performance of BioNTech SE stock is 435.56%, while year-to-date (YTD) performance is 309.08%. BNTX stock has a five-year performance of %. Its 52-week range is between 61.27 and 464, which gives BNTX stock a 52-week price range ratio of 67.59%
BioNTech SE currently has a PE ratio of 19.90, a price-to-book (PB) ratio of 13.97, a price-to-sale (PS) ratio of 8.94, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of 80.46%, a ROC of 126.76% and a ROE of 133.85%. The company’s profit margin is 52.41%, its EBITDA margin is 73.60%, and its revenue ttm is $9.20 Billion , which makes it $37.93 revenue per share.
Of the last four earnings reports from BioNTech SE, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $10.68 for the next earnings report. BioNTech SE’s next earnings report date is 09th Nov 2021.
The consensus rating of Wall Street analysts for BioNTech SE is Moderate Buy (2.14), with a target price of $290.88, which is -12.77% compared to the current price. The earnings rating for BioNTech SE stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioNTech SE has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioNTech SE has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.34, ATR14 : 22.28, CCI20 : -41.43, Chaikin Money Flow : -0.07, MACD : 0.83, Money Flow Index : 57.70, ROC : -0.82, RSI : 47.03, STOCH (14,3) : 21.02, STOCH RSI : 0.00, UO : 48.32, Williams %R : -78.98), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioNTech SE in the last 12-months were:
Thu, 23 Sep 2021 11:50 GMT Pfizer-BioNTech Booster Dose Bags FDA Approval- TipRanks. All rights reserved.
Mon, 06 Sep 2021 17:41 GMT Can Investors Buy at Modernas Current Valuation- TipRanks. All rights reserved.
Tue, 31 Aug 2021 10:25 GMT Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Anixa Biosciences (ANIX)- TipRanks. All rights reserved.
Thu, 26 Aug 2021 09:32 GMT BioNTechs Capabilities Questionable, Despite Vaccine Victory- TipRanks. All rights reserved.
Tue, 24 Aug 2021 09:47 GMT Pfizer-BioNTechs COVID-19 Vaccine Bags Full FDA Approval- TipRanks. All rights reserved.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.